4.8 Review

Directing evolution of novel ligands by mRNA display

Journal

CHEMICAL SOCIETY REVIEWS
Volume 50, Issue 16, Pages 9055-9103

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/d1cs00160d

Keywords

-

Funding

  1. UT MDACC Startup Funds (SWM)
  2. Cancer Prevention and Research Institute of Texas (CPRIT) [RP200166-IIRA]
  3. University of Texas MD Anderson Cancer Center Institutional Research Grant
  4. National Institutes of Health [R44CA206771, R01CA170820, R01CA231509]
  5. Glioblastoma Research Foundation (The Lee Project)
  6. G. E. In-kind Multi-Investigator Imaging (MI2) Research Award
  7. Department of Defense/CDMRP [CA140291]
  8. Ming Hsieh Institute for Research on Engineering-Medicine for Cancer
  9. [T32A196561]

Ask authors/readers for more resources

mRNA display is a powerful platform for directed evolution of proteins and peptides, linking phenotype and genotype through puromycin. Iterative selection cycles lead to peptides with desired functional levels. This review discusses the development and broad application of mRNA display technology in selecting novel peptides and proteins.
mRNA display is a powerful biological display platform for the directed evolution of proteins and peptides. mRNA display libraries covalently link the displayed peptide or protein (phenotype) with the encoding genetic information (genotype) through the biochemical activity of the small molecule puromycin. Selection for peptide/protein function is followed by amplification of the linked genetic material and generation of a library enriched in functional sequences. Iterative selection cycles are then performed until the desired level of function is achieved, at which time the identity of candidate peptides can be obtained by sequencing the genetic material. The purpose of this review is to discuss the development of mRNA display technology since its inception in 1997 and to comprehensively review its use in the selection of novel peptides and proteins. We begin with an overview of the biochemical mechanism of mRNA display and its variants with a particular focus on its advantages and disadvantages relative to other biological display technologies. We then discuss the importance of scaffold choice in mRNA display selections and review the results of selection experiments with biological (e.g., fibronectin) and linear peptide library architectures. We then explore recent progress in the development of drug-like peptides by mRNA display through the post-translational covalent macrocyclization and incorporation of non-proteogenic functionalities. We conclude with an examination of enabling technologies that increase the speed of selection experiments, enhance the information obtained in post-selection sequence analysis, and facilitate high-throughput characterization of lead compounds. We hope to provide the reader with a comprehensive view of current state and future trajectory of mRNA display and its broad utility as a peptide and protein design tool.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available